The earnings call presented a positive outlook, with strategic partnerships, global expansion, and financial strength highlighting growth potential. However, challenges remain in the U.S. market due to pricing pressures and revenue decline.

Company Guidance -

Q3 2025

During Amarin Corporation's second quarter 2025 financial results call, several key metrics and strategic updates were highlighted. The company reported a total net revenue of $72.7 million, marking an 8% increase from the prior year, primarily due to a partnership with Recordati. This partnership is expected to enhance VAZKEPA's commercialization in Europe, leading to increased patient penetration and structured royalty streams. The company anticipates operating expense savings of approximately $70 million over the next 12 months through a global restructuring. This is expected to position the company on an accelerated path to positive cash flow. In the U.S., net product revenue was $36.5 million, indicating a 17% decline due to generic pricing pressures, but market share improved to around 50% in July. European product revenue nearly doubled to $6.6 million, driven by growth in Spain and the U.K., while Rest of World markets showed significant growth with product revenue at $3.5 million. The company is also evaluating further strategic opportunities to enhance shareholder value with Barclays as their financial adviser.

Strategic Partnership with Recordati

Amarin entered into a long-term licensing and supply agreement with Recordati, expected to accelerate the commercialization of VAZKEPA across Europe and increase patient penetration, resulting in structured royalty streams and sales milestones.

Significant Operating Expense Savings

The company announced a restructuring that is anticipated to save approximately $70 million in operating expenses over the next 12 months.

Global Expansion and Demand Growth

VASCEPA saw considerable demand growth in Europe, Rest of World, and China with respective increases of 132%, 68%, and strong growth figures in Australia (75%) and Canada (31%).

Strong Financial Foundation

Amarin reported nearly $300 million in cash, no debt, and sufficient on-hand inventory levels to meet global demand, positioning the company on an accelerated path to positive cash flow.

U.S. Market Performance

Despite ongoing pricing pressure and competition, the U.S. market showed a 7% volume rebound in Q2 2025, with market share stable at 43%.

Amarin (AMRN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMRN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.39 / -	-1.2	―	―	―
Jul 30, 2025	2025 (Q2)	-0.25 / -0.03	0	―	―
May 07, 2025	2025 (Q1)	-0.77 / -0.04	-0.4	90.00% (+0.36)
Mar 12, 2025	2024 (Q4)	-1.06 / -2.40	-0.2	-1100.00% (-2.20)	―
Oct 30, 2024	2024 (Q3)	-1.11 / -1.20	-1	-20.00% (-0.20)	―
Jul 31, 2024	2024 (Q2)	-0.85 / 0.00	-0.8	―
May 01, 2024	2024 (Q1)	-0.60 / -0.40	-0.8	50.00% (+0.40)	―
Feb 29, 2024	2023 (Q4)	-0.54 / -0.20	0	―
Nov 01, 2023	2023 (Q3)	-0.90 / -1.00	-0.2	-400.00% (-0.80)
Aug 02, 2023	2023 (Q2)	-0.80 / -0.80	-3.6	77.78% (+2.80)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AMRN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$14.65	$14.97	+2.18%
May 07, 2025	$10.19	$10.18	-0.10%
Mar 12, 2025	$9.41	$8.00	-14.98%
Oct 30, 2024	$12.04	$11.59	-3.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Amarin Corporation Plc (AMRN) report earnings?

Amarin Corporation Plc (AMRN) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is Amarin Corporation Plc (AMRN) earnings time?

Amarin Corporation Plc (AMRN) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AMRN EPS forecast?

AMRN EPS forecast for the fiscal quarter 2025 (Q3) is -0.39.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing